Merck Secures FDA Nod for ENFLONSIA, Projects $50 B Pipeline Revenue
BMY•Merck’s late-stage pipeline nearly tripled to over 20 assets by October 2024, underpinning a $50 billion revenue opportunity. On June 9, 2025 the FDA approved ENFLONSIA for RSV prevention and reported positive Phase 3 results for cholesterol drug Enlicitide, delivering the first concrete validation of this pipeline.
1. Pipeline Expansion and Revenue Opportunity
Merck’s late-stage pipeline has nearly tripled over the past three years to more than 20 unique assets, with management forecasting over $50 billion in potential revenue from these programs based on discussions in earnings calls from October 2024 through April 2025.
2. FDA Approval of ENFLONSIA
On June 9, 2025 the FDA approved ENFLONSIA for RSV prevention in infants, representing the first major regulatory milestone and signaling the start of tangible returns from the company’s expanded pipeline.
3. Positive Phase 3 Enlicitide Results
Simultaneously, Merck announced positive topline results from Phase 3 trials of its cholesterol drug Enlicitide, marking a second critical validation point and reinforcing expectations for multiple near-term product launches.
4. Elevated Options Market Reaction
In the weeks leading up to these announcements, implied volatility for Merck options sat in the 87th percentile of its one-year range, indicating that traders were anticipating a significant stock move tied to pipeline catalysts.
